GlassScriptPhysician profile
Michele Kane
NPI 1578082376
$1,809.69
in general payments reported to CMS, 2019-2025
14 companies · $518 in 2025
The $518 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2023: $267 · 2024: $792 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $345.14 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $331.07 | 2023-2025 | Infuse, Biotrue One Day, Miebo |
| Tarsus Pharmaceuticals, INC. | $269.72 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $190.83 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Harrow Eye, LLC | $139.15 | 2024-2025 | Vevye, Iheezo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $120.63 | 2019 | |
| Dompe US, INC. | $116.11 | 2024-2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $69.40 | 2019 | |
| Alcon Vision LLC | $59.21 | 2023-2025 | Rocklatan |
| Biotissue Holdings INC. | $45.58 | 2024 | |
| Visioneering Technologies, INC. | $42.64 | 2019 | |
| Glaukos Corporation | $36.51 | 2025 | Idosetr |
| Sun Pharmaceutical Industries INC. | $27.26 | 2025 | |
| Thea Pharma INC. | $16.44 | 2024 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Kane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.